Trials / Sponsors / Genelux Corporation
Genelux Corporation
Industry · 5 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 2 | 2024-09-26 |
| Recruiting | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherap Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | 2022-08-31 |
| Completed | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer | Phase 1 / Phase 2 | 2016-05-01 |
| Completed | Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer Cancer of Head and Neck | Phase 1 | 2012-04-01 |
| No Longer Available | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients) | — | — |